IP Library Granted Patent US 8,349,348
Granted Patent B2
US 8,349,348 · App. 12/510,890 · Granted Jan 8, 2013

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,349,348
App. No.
12/510,890
Granted
Jan 8, 2013
Kind
B2
Abstract

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Claims (27)

1. A crosslinking composition produced by maintaining an initial dialdehyde composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days.

2. The crosslinking composition according to claim 1 , wherein the initial dialdehyde is glutaraldehyde.

3. The crosslinking composition according to claim 2 , wherein the crosslinking composition comprises molecules described by the following formula:

wherein R 1 and R 2 are H or hydrocarbon moieties which are polymerization products produced by sequential aldol reaction and dehydration of one or more glutaraldehyde molecules.

4. The crosslinking composition according to claim 3 , wherein the crosslinking composition comprises crosslinking molecules described by the formula:

5. The crosslinking composition according to claim 3 , wherein upon combination with a proteinaceous substrate the crosslinking composition produces a pyridinium moiety-containing crosslinking structure.

6. A kit comprising:

(a) a substrate comprising a proteinaceous substrate; and

(b) a crosslinking composition produced by maintaining an initial glutaraldehyde composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days.

7. The kit according to claim 6 , wherein the crosslinking composition comprises molecules described by the following formula:

wherein R 1 and R 2 are H or hydrocarbon moieties which are polymerization products produced by sequential aldol reaction and dehydration of one or more glutaraldehyde molecules.

8. The kit according to claim 7 , wherein the crosslinking composition comprises molecules described by the formula:

9. The kit according to claim 7 , wherein upon combination with a proteinaceous substrate the crosslinking composition produces a pyridinium moiety-containing crosslinking structure.

10. The kit according to claim 6 , wherein the proteinaceous substrate comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof.

11. The kit according to claim 6 , wherein said substrate further comprises an adhesion modifier.

12. The kit according to claim 6 , wherein said substrate further comprises a plasticizer.

13. The kit according to claim 6 , wherein the substrate further comprises a carbohydrate.

14. The kit according to claim 6 , wherein said substrate further comprises a filler.

15. The kit according to claim 6 , wherein said substrate further comprises a polyblend.

16. The kit according to claim 6 , wherein said substrate further comprises a biologically active agent.

17. The kit according to claim 6 , wherein said substrate further comprises a foaming agent.

18. The kit according to claim 6 , wherein the kit further comprises a delivery device for delivering a phase invertible composition produced by combining the substrate and the crosslinking composition.

19. A phase invertible composition produced by combining:

(a) a substrate comprising a proteinaceous substrate; and

(b) a crosslinking composition produced by maintaining an initial dialdehyde composition at a temperature ranging from about 45 to about 55° C. for a period of time ranging from about 1 to about 20 days,

wherein the crosslinking composition produces a pyridinium moiety-containing crosslinking structure upon combination with the proteinaceous substrate.

20. The phase invertible composition according to claim 19 , wherein the initial dialdehyde is glutaraldehyde.

Assignments (6)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2018
From: MATRIX MEDICAL, LLC
To: TENAXIS MEDICAL, INC.
Reel/Frame 046066/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045754/0904 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 3, 2017
From: TENAXIS MEDICAL, INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043767/0923 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2009
From: SCHANKERELI, KEMAL; DIECK, RONALD
To: MATRIX MEDICAL LLC
Reel/Frame 023137/0437 →